Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome

Breast Cancer Research and Treatment

Volumn 122, Issue 2, 2010, Pages 347-357

  Murrow, Lyndsay M ^a   Garimella, Sireesha V ^a   Jones, Tamara L ^a   Caplen, Natasha J ^a   Lipkowitz, Stanley ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis.; Breast cancer; RNAi screen; Tyrosine kinase; WEE1

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CELL CYCLE PROTEIN; CELL DNA; GAMMA HISTONE H2AX; HISTONE; LIPOCORTIN 5; PROTEIN TYROSINE KINASE; PROTEIN WEE1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CASPASE INHIBITOR; CYSTEINE PROTEINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; H2AFX PROTEIN, HUMAN; NUCLEAR PROTEIN; PROGESTERONE RECEPTOR; PROTEIN KINASE INHIBITOR; WEE1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL STRAIN MCF 7; CELL STRUCTURE; CONTROLLED STUDY; DNA CONTENT; DNA DAMAGE; DRUG TARGETING; ENZYME ACTIVATION; EPITHELIUM CELL; GENE SILENCING; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SYNTHESIS INHIBITION; RNA INTERFERENCE; STAINING; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TIME; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CASPASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYSTEINE PROTEINASE INHIBITORS; FEMALE; HISTONES; HUMANS; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA INTERFERENCE; TIME FACTORS; CASPASE INHIBITORS;

EID: 77955655940     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0571-2     Document Type: Article

References (41)

1. Brenton JD, Carey LA, Ahmed AA, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23(29):7350-7360.
2. Irvin WJ Jr, Carey LA (2008) What is triple-negative breast cancer? Eur J Cancer 44(18):2799-2805.
3. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874.
4. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, Birnbaum D (2008) How basal are triple-negative breast cancers? Int J Cancer 123(1):236-240.
5. Charafe-Jauffret E, Ginestier C, Monville F et al (2006) Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25(15):2273-2284.
6. Neve RM, Chin K, Fridlyand J et al (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6):515-527.
7. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298(5600):1912-1934.
8. Hunter T (1987) A thousand and one protein kinases. Cell 50(6): 823-829.
9. Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353(2):172-187.
10. MacKeigan JP, Murphy LO, Blenis J (2005) Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 7(6):591-600.
11. Bettencourt-Dias M, Giet R, Sinka R et al (2004) Genome-wide survey of protein kinases required for cell cycle progression. Nature 432(7020):980-987.
12. Giroux V, Iovanna J, Dagorn JC (2006) Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB J 20(12):1982-1991.
13. Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS, Lipkowitz S (2009) TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 113(2):217-230.
14. http://www.stanford.edu/group/gozani/Histone%20extraction%20protocol.pdf [cited].
15. McGowan CH, Russell P (1993) Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J 12(1):75-85.
16. Palmer BD, Thompson AM, Booth RJ et al (2006) 4-Phenylpyrrolo[ 3, 4-c]carbazole-1, 3(2H, 6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution. J Med Chem 49(16): 4896-4911.
17. Iorns E, Lord CJ, Grigoriadis A et al (2009) Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS ONE 4(4):e5120.
18. Niida H, Nakanishi M (2006) DNA damage checkpoints in mammals. Mutagenesis 21(1):3-9.
19. Rogakou EP, Boon C, Redon C, Bonner WM (1999) Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 146(5):905-916.
20. Tyner JW, Walters DK, Willis SG et al (2008) RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood 111(4):2238-2245.
21. O'Connell MJ, Raleigh JM, Verkade HM, Nurse P (1997) Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J 16(3):545-554.
22. Yuli C, Shao N, Rao R et al (2007) BRCA1a has antitumor activity inTNbreast, ovarian and prostate cancers. Oncogene 26(41):6031-6037.
23. Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR, Sun Y (2001) Radiosensitization of p53 mutant cells by PD0166 285, a novel G(2) checkpoint abrogator. Cancer Res 61 (22):8211-8217.
24. Li J, Wang Y, Sun Y, Lawrence TS (2002) Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor. Radiat Res 157(3):322-330.
25. Wang Y, Decker SJ, Sebolt-Leopold J (2004) Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 3(3):305-313.
26. Hashimoto O, Shinkawa M, Torimura T, Nakamura T, Selvendiran K, Sakamoto M, Koga H, Ueno T, Sata M (2006) Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2, 3-d] pyrimidine, in the B16 mouse melanoma cell line. BMC Cancer 6:292.
27. Syljuasen RG, Sorensen CS, Hansen LT et al (2005) Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 25(9):3553-3562.
28. Niida H, Tsuge S, Katsuno Y, Konishi A, Takeda N, Nakanishi M (2005) Depletion of Chk1 leads to premature activation of Cdc2- cyclin B and mitotic catastrophe. J Biol Chem 280(47):39246-39252.
29. Sidi S, Sanda T, Kennedy RD et al (2008) Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 133(5):864-877.
30. Turner N, Tutt A, Ashworth A (2004) Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4(10):814-819.
31. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6):622-629.
32. Chauvier D, Lecoeur H, Langonne A, Borgne-Sanchez A, Mariani J, Martinou JC, Rebouillat D, Jacotot E (2005) Upstream control of apoptosis by caspase-2 in serum-deprived primary neurons. Apoptosis 10(6):1243-1259.
33. Gregoli PA, Bondurant MC (1999) Function of caspases in regulating apoptosis caused by erythropoietin deprivation in erythroid progenitors. J Cell Physiol 178(2):133-143.
34. Pereira NA, Song Z (2008) Some commonly used caspase substrates and inhibitors lack the specificity required to monitor individual caspase activity. Biochem Biophys Res Commun 377 (3):873-877.
35. Schellens JH, Leijen S, Shaprio GI et al. (2009) A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol 27(15s):148s.
36. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, Pommier Y (2008) GammaH2AX and cancer. Nat Rev Cancer 8(12):957-967.
37. Sedelnikova OA, Bonner WM (2006) GammaH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle 5(24):2909-2913.
38. Hong Y, Cervantes RB, Tichy E, Tischfield JA, Stambrook PJ (2007) Protecting genomic integrity in somatic cells and embryonic stem cells. Mutat Res 614(1-2):48-55.
39. Opar A (2009) Novel anticancer strategy targets DNA repair. Nat Rev Drug Discov 8(6):437-438.
40. O'Shaughnessy J, Osborne C, Pippen J et al (2009) Efficacy of BSI-201, a poly(ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomised phase II trial. J Clin Oncol 27(15s):6s.
41. Ashwell S, Zabludoff S (2008) DNA damage detection and repair pathways-recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 14(13):4032-4037.